期刊文献+

HPLC测定瑞格列奈片的含量

Content Determination of Repaglinide Tablets by HPLC
下载PDF
导出
摘要 目的:建立瑞格列奈片的含量测定方法。方法:采用高效液相色谱法对瑞格列奈成分进行含量测定。色谱柱:DIKMA Diamonsil C_(18)(2)(250 mm×4.6 mm,5μm);流动相:醋酸铵缓冲液(取醋酸铵3.85 g,加水1000 m L溶解后,用冰醋酸调pH值至4.0)-甲醇(20∶80)为流动相;流速:1.0 m L/min;检测波长为243 nm;柱温为25℃;进样量为20μL。结果:瑞格列奈在10~30μg/m L范围内线性关系良好,相关系数r为0.999 6;平均回收率为100.4%,RSD为1.22%;24 h内瑞格列奈溶液稳定性良好,RSD为1.08%。结论 :本方法操作简便,结果准确、可靠,可用于瑞格列奈片的含量测定。 Objective:To develop a method for determination of content of repaglinide tablets.Methods:HPLC was used for determination of contents of various components of repaglinide tablets.DIKMA Diamonsil C18(2)column(250 mm×4.6 mm,5μm)was adopted serving ammonium acetate buffer(3.85 g ammonium acetate solution dissolved in 1 000 m L of water,of which the pH value was adjusted to 4.0 with acetic acid)-methanol(20︰80)as mobile phase at a flow rate of 1.0 m L/min.The detection wavelength was 243 nm,while the column temperature was 25℃,and the sample loading was 20μL.Results:The linear range of repaglinide was 1030μg/m L,with a r value of 0.999 6.The average recovery was 100.4%,with a RSD of 1.22%.The repaglinide solution showed good stability within 24 h,with a RSD of 1.08%.Conclusion:This method is simple,accurate and reliable,which is applicable for the quality control of repaglinide tablets.
作者 何小琳 张颖 董爽 王迷娟 He Xiao-lin;Zhang Ying;Dong Shuang;Wang Mi-juan(Beijing Union Pharmaceutical Factory,Beijing 102600,China;The Second Union Pharmaceutical Factory of Beijing City,Beijing 102600,China)
出处 《中国执业药师》 CAS 2017年第6期64-66,70,共4页 China Licensed Pharmacist
关键词 高效液相色谱法 瑞格列奈片 含量 HPLC Repaglinide Tablets Content
  • 相关文献

参考文献6

二级参考文献67

  • 1刘丹,傅祖植.二甲双胍临床应用中的几个问题[J].中华糖尿病杂志(1006-6187),2005,13(2):149-150. 被引量:38
  • 2Bailey C, Del Pinto S, Eddy DM, et al. Eearlier intervention in type2 diabetes: the case for achieving early and sustained glycaemic control [ J]. Int J Clin Pract, 2005,59( 11 ) : 1309.
  • 3UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with meffonnin on complications in overweight patients with type 2 diabetes(UKPDS34) [J].Lancet , 1998,352(9131 ): 854.
  • 4Akalin S , Bemtorp K , Ceriello A, et al. Intensive glucose therapy and clinical implications of recent data: a eonsensus statement from the Glob- Task Force on Glycaenfic Control[ J ]. Int J Clin Pratt, 2009,63 ( 10 ), 1421.
  • 5Del Prato S, Felton AM, Munro N, et al. Improving glucose management: ten steps to get more patient with type 2 diabetes to glycaemic goal (recommendations from the global partnership for effective diabetes man- agement)[J], lnt J Clin Pract,2007,157 (Suppl), 47.
  • 6Writing Team for the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and pmbcession of diabetic nephropathy: the epidemiolgy of diabetes interventions and complications(EDIC) study[ J]. JAMA, 2003, 290(16) :2159.
  • 7Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus [ J ]. Diabetes Metab Rev,2007,17(3) : 164.
  • 8瑞格列奈片说明书[EB/OL].http://www.sda.gov.cndaysms3/062.htm.2010-08-12.
  • 9Bailey CJ. Biguanides and NIDDDM[ J ].Diabetes Care, 1992, 15 : 755.
  • 10Mukai E, Ishida H, Fujimoto S, et al. The insulinotropic mechanism of the novel hypoglycaemic agent JTT-608: direct enhancement of Ca2 + efficacy and increase of Ca2 + influx by phosphodiesterase inhibition[J]. Br J Pharmacol,2000,129( 5 ) :901.

共引文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部